Antibodies to citrullinated proteins: Molecular interactions and arthritogenicity

Immunological Reviews

Volumn 233, Issue 1, 2010, Pages 9-33

  Uysal, Hüseyin ^a   Nandakumar, Kutty Selva ^a   Kessel, Christoph ^a   Haag, Sabrina ^a   Carlsen, Stefan ^a   Burkhardt, Harald ^b   Holmdahl, Rikard ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Cartilage; Citrullination; Monoclonal antibody; Rheumatoid arthritis; Type II collagen

Indexed keywords

ANTI CITRULLINATED PROTEIN ANTIBODY; AUTOANTIBODY; COLLAGEN TYPE 2; PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CARBAMOYLATION; ENZYME MODIFICATION; IMMUNOTHERAPY; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR INTERACTION; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN CITRULLINATION; PROTEIN MODIFICATION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODY SPECIFICITY; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNITY; CITRULLINE; COLLAGEN TYPE II; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INFLAMMATION MEDIATORS; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 73249142493     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2009.00853.x     Document Type: Review

References (230)

1. Uy R, Wold F. Posttranslational covalent modification of proteins. Science 1977 198 : 890 896.
2. Newkirk MM, et al. Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Res Ther 2003 5 : R82 R90.
3. Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL. Post-translational modifications of naturally processed MHC-binding epitopes. Curr Opin Immunol 2006 18 : 92 97.
4. Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT. When does rheumatoid disease start? Arthritis Rheum 1985 28 : 485 489.
5. Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 1964 23 : 302 305.
6. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979 2 : 97 99.
7. Sebbag M, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995 95 : 2672 2679.
8. Simon M, et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993 92 : 1387 1393.
9. Simon M, et al. Monoclonal antibodies to human epidermal filaggrin, some not recognizing profilaggrin. J Invest Dermatol 1995 105 : 432 437.
10. Simon M, et al. The rheumatoid arthritis-associated autoantibodies to filaggrin label the fibrous matrix of the cornified cells but not the profilaggrin-containing keratohyalin granules in human epidermis. Clin Exp Immunol 1995 100 : 90 98.
11. Palosuo T, et al. Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int J Allergy Immunol 1998 115 : 294 302.
12. Masson-Bessiere C, et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 2000 119 : 544 552.
13. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998 101 : 273 281.
14. Girbal-Neuhauser E, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999 162 : 585 594.
15. Burkhardt H, Sehnert B, Bockermann R, Engström A, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005 35 : 1643 1652.
16. Masson-Bessiere C, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001 166 : 4177 4184.
17. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology (Oxford) 2005 44 : 1374 1382.
18. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004 50 : 3485 3494.
19. Kinloch A, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005 7 : R1421 R1429.
20. Okazaki Y, et al. Identification of citrullinated eukaryotic translation initiation factor 4G1 as novel autoantigen in rheumatoid arthritis. Biochem Biophys Res Commun 2006 341 : 94 100.
21. Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P. Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 2006 33 : 647 651.
22. Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006 54 : 733 741.
23. Schellekens GA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000 43 : 155 163.
24. Dorow DS, Shi PT, Carbone FR, Minasian E, Todd PE, Leach SJ. Two large immunogenic and antigenic myoglobin peptides and the effects of cyclisation. Mol Immunol 1985 22 : 1255 1264.
25. Nishimura K, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Int Med 2007 146 : 797 808.
26. Perez ML, Gomara MJ, Ercilla G, Sanmarti R, Haro I. Antibodies to citrullinated human fibrinogen synthetic peptides in diagnosing rheumatoid arthritis. J Med Chem 2007 50 : 3573 3584.
27. Despres N, Boire G, Lopez-Longo FJ, Menard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994 21 : 1027 1033.
28. Hayem G, et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 1999 26 : 7 13.
29. Vossenaar ER, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004 63 : 373 381.
30. Asaga H, Yamada M, Senshu T. Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun 1998 243 : 641 646.
31. Moisan E, Girard D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J Leukoc Biol 2006 79 : 489 498.
32. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003 5 : 59 63.
33. Bang H, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007 56 : 2503 2511.
34. Mathsson L, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008 58 : 36 45.
35. Ursum J, et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 2008 10 : R12.
36. Soos L, et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 2007 34 : 1658 1663.
37. Aho K, Palosuo T, Heliovaara M, Knekt P, Alha P, von Essen R. Antifilaggrin antibodies within "normal" range predict rheumatoid arthritis in a linear fashion. J Rheumatol 2000 27 : 2743 2746.
38. Kurki P, Aho K, Palosuo T, Heliovaara M. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992 35 : 914 917.
39. Rantapaa-Dahlqvist S, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003 48 : 2741 2749.
40. Nielen MM, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004 50 : 380 386.
41. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 2003 25 : 1106 1118.
42. Foulquier C, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007 56 : 3541 3553.
43. Asaga H, Nakashima K, Senshu T, Ishigami A, Yamada M. Immunocytochemical localization of peptidylarginine deiminase in human eosinophils and neutrophils. J Leukoc Biol 2001 70 : 46 51.
44. Nakashima K, Hagiwara T, Yamada M. Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J Biol Chem 2002 277 : 49562 49568.
45. Chavanas S, et al. Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6. Gene 2004 330 : 19 27.
46. Wright PW, et al. ePAD, an oocyte and early embryo-abundant peptidylarginine deiminase-like protein that localizes to egg cytoplasmic sheets. Dev Biol 2003 256 : 73 88.
47. Senshu T, Kan S, Ogawa H, Manabe M, Asaga H. Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis. Biochem Biophys Res Commun 1996 225 : 712 719.
48. Pritzker LB, Nguyen TA, Moscarello MA. The developmental expression and activity of peptidylarginine deiminase in the mouse. Neurosci Lett 1999 266 : 161 164.
49. Esposito G, et al. Peptidylarginine deiminase (PAD) 6 is essential for oocyte cytoskeletal sheet formation and female fertility. Mol Cell Endocrinol 2007 273 : 25 31.
50. Rogers G, Winter B, McLaughlan C, Powell B, Nesci T. Peptidylarginine deiminase of the hair follicle: characterization, localization, and function in keratinizing tissues. J Invest Dermatol 1997 108 : 700 707.
51. Neeli I, Khan SN, Radic M. Histone deimination as a response to inflammatory stimuli in neutrophils. J Immunol 2008 180 : 1895 1902.
52. Wang Y, et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol 2009 184 : 205 213.
53. Cobb BA, Wang Q, Tzianabos AO, Kasper DL. Polysaccharide processing and presentation by the MHCII pathway. Cell 2004 117 : 677 687.
54. Raijmakers R, et al. Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro. J Mol Biol 2007 367 : 1118 1129.
55. Nakayama-Hamada M, et al. Comparison of enzymatic properties between hPADI2 and hPADI4. Biochem Biophys Res Commun 2005 327 : 192 200.
56. Arita K, Hashimoto H, Shimizu T, Nakashima K, Yamada M, Sato M. Structural basis for Ca(2+)-induced activation of human PAD4. Nat Struct Mol Biol 2004 11 : 777 783.
57. Arita K, Shimizu T, Hashimoto H, Hidaka Y, Yamada M, Sato M. Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4. Proc Natl Acad Sci USA 2006 103 : 5291 5296.
58. Lewis RS. Calcium signaling mechanisms in T lymphocytes. Annu Rev Immunol 2001 19 : 497 521.
59. Kearney PL, et al. Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis. Biochemistry 2005 44 : 10570 10582.
60. Stensland ME, Pollmann S, Molberg O, Sollid LM, Fleckenstein B. Primary sequence, together with other factors, influence peptide deimination by peptidylarginine deiminase-4. Biol Chem 2009 390 : 99 107.
61. Schwab BL, et al. Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis. Cell Death Differ 2002 9 : 818 831.
62. Wood DD, et al. Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities. Lab Invest 2008 88 : 354 364.
63. Proost P, et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med 2008 205 : 2085 2097.
64. Struyf S, et al. Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4. J Immunol 2009 182 : 666 674.
65. Loos T, et al. Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Blood 2008 112 : 2648 2656.
66. Stim J, Shaykh M, Anwar F, Ansari A, Arruda JA, Dunea G. Factors determining hemoglobin carbamylation in renal failure. Kidney Int 1995 48 : 1605 1610.
67. Wang Z, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007 13 : 1176 1184.
68. Tarkowski A, Klareskog L, Carlsten H, Herberts P, Koopman WJ. Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum 1989 32 : 1087 1092.
69. Terato K, et al. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum 1990 33 : 1493 1500.
70. Cook AD, Gray R, Ramshaw J, Mackay IR, Rowley MJ. Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis. Arthritis Res Ther 2004 6 : R477 R483.
71. Cook AD, Rowley MJ, Mackay IR, Gough A, Emery P. Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum 1996 39 : 1720 1727.
72. Kraetsch HG, et al. Cartilage-specific autoimmunity in rheumatoid arthritis: characterization of a triple helical B cell epitope in the integrin- binding-domain of collagen type II. Eur J Immunol 2001 31 : 1666 1673.
73. Burkhardt H, et al. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum 2002 46 : 2339 2348.
74. Nandakumar KS, et al. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheum 2008 58 : 184 196.
75. Cook AD, et al. Antibodies to type II collagen and HLA disease susceptibility markers in rheumatoid arthritis. Arthritis Rheum 1999 42 : 2569 2576.
76. Engvall E, Rouslahti E, Miller EJ. Affinity of fibronectin to collagens of different genetic types and to fibirnogen. J Exp Med 1978 148 : 1584 1595.
77. Bajtner E, Nandakumar KS, Engström Å, Holmdahl R. Chronic development of collagen-induced arthritis is associated with arthritogenic antibodies against specific epitopes on type II collagen. Arthritis Res Ther 2005 7 : R1148 R1157.
78. Mo JA, Scheynius A, Nilsson S, Holmdahl R. Germline-encoded IgG antibodies bind mouse cartilage in vivo: epitope- and idiotype-specific binding and inhibition. Scand J Immunol 1994 39 : 122 130.
79. Mo JA, Bona CA, Holmdahl R. Variable region gene selection of immunoglobulin G-expressing B cells with specificity for a defined epitope on type II collagen. Eur J Immunol 1993 23 : 2503 2510.
80. Holmdahl R, Andersson M, Jansson L. A method for the analysis of a large number of specific and multispecific B cell hybridomas derived from primary immunized lymph nodes. Hybridoma 1987 6 : 197 204.
81. Holmdahl R, et al. Origin of the autoreactive anti type II collagen response. II. Specificities, isotypes and usage of V gene families of anti type II collagen autoantibodies. J Immunol 1989 142 : 881 886.
82. Wernhoff P, Unger C, Bajtner E, Burkhardt H, Holmdahl R. Identification of conformation-dependent epitopes and V gene selection in the B cell response to type II collagen in the DA rat. Int Immunol 2001 13 : 909 919.
83. Schulte S, et al. Arthritis-related B cell epitopes in collagen II are conformation- dependent and sterically privileged in accessible sites of cartilage collagen fibrils. J Biol Chem 1998 273 : 1551 1561.
84. Holmdahl R, Rubin K, Klareskog L, Larsson E, Wigzell H. Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. Arthritis Rheum 1986 29 : 400 410.
85. Burkhardt H, et al. Association between protein tyrosine phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope and humoral autoimmunity to an immunodominant epitope of cartilage-specific type II collagen in early rheumatoid arthritis. Arthritis Rheum 2006 54 : 82 89.
86. Yamada H, Dzhambazov B, Bockermann R, Blom T, Holmdahl R. A transient post-translationally modified form of cartilage type II collagen is ignored by self-reactive T cells. J Immunol 2004 173 : 4729 4735.
87. Dzhambazov B, et al. The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans. Eur J Immunol 2005 35 : 357 366.
88. Slatter DA, Paul RG, Murray M, Bailey AJ. Reactions of lipid-derived malondialdehyde with collagen. J Biol Chem 1999 274 : 19661 19669.
89. Daumer KM, Khan AU, Steinbeck MJ. Chlorination of pyridinium compounds. Possible role of hypochlorite, N- chloramines, and chlorine in the oxidation of pyridinoline cross-links of articular cartilage collagen type II during acute inflammation. J Biol Chem 2000 275 : 34681 34692.
90. Uysal H, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009 206 : 449 462.
91. Klareskog L, Johnell O, Hulth A, Holmdahl R, Rubin K. Reactivity of monoclonal anti-type II collagen antibodies with cartilage and synovial tissue in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1986 29 : 730 738.
92. Tsark EC, Wang W, Teng YC, Arkfeld D, Dodge GR, Kovats S. Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages. J Immunol 2002 169 : 6625 6633.
93. Holmdahl R, Mo JA, Jonsson R, Karlström K, Scheynius A. Multiple epitopes on cartilage type II collagen are accessible for antibody binding in vivo. Autoimmunity 1991 10 : 27 34.
94. Boiers U, Lanig H, Sehnert B, Holmdahl R, Burkhardt H. Collagen type II is recognized by a pathogenic antibody through germline encoded structures. Eur J Immunol 2008 38 : 2784 2795.
95. Vossenaar ER, et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003 48 : 2489 2500.
96. Kuhn KA, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006 116 : 961 973.
97. Kidd BA, et al. Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis Res Ther 2008 10 : R119.
98. Nicholas AP, et al. Immunohistochemical localization of citrullinated proteins in adult rat brain. J Comp Neurol 2003 459 : 251 266.
99. Johannesson M, et al. Identification of epistasis through a partial advanced intercross reveals three arthritis loci within the Cia5 QTL in mice. Genes Immun 2005 6 : 175 185.
100. Moscarello MA, Wood DD, Ackerley C, Boulias C. Myelin in multiple-sclerosis is developmentally immature. J Clin Invest 1994 94 : 146 154.
101. Raijmakers R, Vogelzangs J, Croxford JL, Wesseling P, Van Venrooij WJ, Pruijn GJM. Citrullination of central nervous system proteins during the development of experimental autoimmune encephalomyelitis. J Comp Neurol 2005 486 : 243 253.
102. Ishigami A, et al. Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. J Neurosci Res 2005 80 : 120 128.
103. Chapuy-Regaud S, et al. Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides. J Immunol 2005 174 : 5057 5064.
104. Makrygiannakis D, et al. Citrullination is an inflammation-dependent process. Ann Rheum Dis 2006 65 : 1219 1222.
105. Suzuki A, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003 34 : 395 402.
106. Kang CP, Lee HS, Ju H, Cho H, Kang C, Bae SC. A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis Rheum 2006 54 : 90 96.
107. Barton A, et al. A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis Rheum 2004 50 : 1117 1121.
108. Caponi L, et al. A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann Rheum Dis 2005 64 : 587 593.
109. Martinez A, et al. PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population. Rheumatology (Oxford) 2005 44 : 1263 1266.
110. Hoppe B, et al. Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis. Ann Rheum Dis 2009 68 : 898 903.
111. Huffmeier U, Boiers U, Lascorz J, Reis A, Burkhardt H. Loss-of-function mutations in the filaggrin gene: no contribution to disease susceptibility, but to autoantibody formation against citrullinated peptides in early rheumatoid arthritis. Ann Rheum Dis 2008 67 : 131 133.
112. van Gaalen FA, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004 50 : 2113 2121.
113. Irigoyen P, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005 52 : 3813 3818.
114. Huizinga TW, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005 52 : 3433 3438.
115. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006 54 : 1117 1121.
116. van der Helm-van Mil AH, Verpoort KN, le Cessie S, Huizinga TW, de Vries RR, Toes RE. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007 56 : 425 432.
117. Klareskog L, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006 54 : 38 46.
118. Rantapaa-Dahlqvist S, Boman K, Tarkowski A, Hallmans G. Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann Rheum Dis 2007 66 : 121 123.
119. Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther 2006 8 : R19.
120. Kokkonen H, Johansson M, Innala L, Jidell E, Rantapaa-Dahlqvist S. The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther 2007 9 : R56.
121. Plenge RM, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007 39 : 1477 1482.
122. Plenge RM, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005 77 : 1044 1060.
123. Kallberg H, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007 80 : 867 875.
124. Verpoort KN, van Dongen H, Allaart CF, Toes RE, Breedveld FC, Huizinga TW. Undifferentiated arthritis - disease course assessed in several inception cohorts. Clin Exp Rheumatol 2004 22 : S12 S17.
125. Meyer O, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003 62 : 120 126.
126. Kroot EJ, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000 43 : 1831 1835.
127. Rönnelid J, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005 64 : 1744 1749.
128. Pedersen M, et al. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum 2007 56 : 1446 1453.
129. Katz J, Goultschin J, Benoliel R, Brautbar C. Human leukocyte antigen (HLA) DR4. Positive association with rapidly progressing periodontitis. J Periodontol 1987 58 : 607 610.
130. Marotte H, Farge P, Gaudin P, Alexandre C, Mougin B, Miossec P. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis 2006 65 : 905 909.
131. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008 26 : 651 675.
132. Hill JA, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008 204 : 967 979.
133. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003 171 : 538 541.
134. Molberg O, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nature Med 1998 4 : 713 717.
135. Choi EKK, Gatenby PA, McGill NW, Bateman JF, Cole WG, York JR. Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue diseases, and chronic inflammatory syndromes. Ann Rheum Dis 1988 47 : 313 322.
136. Nandakumar KS, Svensson L, Holmdahl R. Collagen type II specific monoclonal antibody induced arthritis (CAIA) in mice. Description of the disease and the influence of age, sex, and genes. Am J Pathol 2003 163 : 1827 1837.
137. Bäcklund J, et al. Predominant selection of T cells specific for glycosylated collagen type II peptide (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA 2002 99 : 9960 9965.
138. Rowley MJ, Nandakumar KS, Holmdahl R. The role of collagen antibodies in mediating arthritis. Mod Rheumatol 2008 18 : 429 441.
139. Flick MJ, et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest 2007 117 : 3224 3235.
140. Lundberg K, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005 7 : R458 R467.
141. Duplan V, et al. In the rat, citrullinated autologous fibrinogen is immunogenic but the induced autoimmune response is not arthritogenic. Clin Exp Immunol 2006 145 : 502 512.
142. Rubin B, Sonderstrup G. Citrullination of self-proteins and autoimmunity. Scand J Immunol 2004 60 : 112 120.
143. Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM. Induction of arthritis with monoclonal antibodies to collagen. J Immunol 1992 148 : 2103 2108.
144. Wooley PH, Luthra HS, Huse AR, Stuart JM, David CS. Passive transfer of arthritis to mice by injection of human anti-type II collagen antibody. Mayo Clinic Proc 1984 59 : 737 743.
145. Petkova SB, Konstantinov KN, Sproule TJ, Lyons BL, Awwami MA, Roopenian DC. Human antibodies induce arthritis in mice deficient in the low-affinity inhibitory IgG receptor Fc gamma RIIB. J Exp Med 2006 203 : 275 280.
146. Stuart JM, Dixon FJ. Serum transfer of collagen induced arthritis in mice. J Exp Med 1983 158 : 378 392.
147. Holmdahl R, Jansson L, Larsson A, Jonsson R. Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-type II collagen auto-antibodies. Scand J Immunol 1990 31 : 147 157.
148. Stuart JM, Cremer MA, Townes AS, Kang AH. Type II collagen induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med 1982 155 : 1 16.
149. Nandakumar KS, et al. Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcgammaRIIB. Eur J Immunol 2003 33 : 2269 2277.
150. Nandakumar KS, Holmdahl R. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods 2005 304 : 126 136.
151. Nandakumar KS, Bäcklund J, Vestberg M, Holmdahl R. Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells. Arthritis Res Ther 2004 6 : R544 R550.
152. Kagari T, Doi H, Shimozato T. The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol 2002 169 : 1459 1466.
153. Nandakumar KS, Johansson B, Björck L, Holmdahl R. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo. Arthritis Rheum 2007 56 : 3253 3260.
154. Adkison AM, Raptis SZ, Kelley DG, Pham CT. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 2002 109 : 363 371.
155. Mullazehi M, Mathsson L, Lampa J, Ronnelid J. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis. Arthritis Rheum 2006 54 : 1759 1771.
156. Mullazehi M, Mathsson L, Lampa J, Ronnelid J. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset. Ann Rheum Dis 2007 66 : 537 541.
157. Watson WC, Townes AS. Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and non-MHC loci. J Exp Med 1985 162 : 1878 1891.
158. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995 92 : 8955 8959.
159. Wang Y, Kristan J, Hao L, Lenkoski CS, Shen Y, Matis LA. A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. J Immunol 2000 164 : 4340 4347.
160. Johansson ÅCM, et al. Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes. Eur J Immunol 2001 31 : 1847 1856.
161. Hietala MA, Jonsson IM, Tarkowski A, Kleinau S, Pekna M. Complement deficiency ameliorates collagen-induced arthritis in mice. J Immunol 2002 169 : 454 459.
162. Banda NK, et al. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum 2002 46 : 3065 3075.
163. Morgan K, Clague RB, Shaw MJ, Firth SA, Twose TM, Holt PJL. Native type II collagen-induced arthritis in the rat. The effect of complement depletion by cobra venom factor. Arthritis Rheum 1981 24 : 1356 1362.
164. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Soluble complement receptor one (sCR1) inhibits the development and progression of rat
165. Banda NK, Kraus DM, Muggli M, Bendele A, Holers VM, Arend WP. Prevention of collagen-induced arthritis in mice transgenic for the complement inhibitor complement receptor 1-related gene/protein y. J Immunol 2003 171 : 2109 2115.
166. Mizuno M, et al. Membrane complement regulators protect against the development of type II collagen-induced arthritis in rats. Arthritis Rheum 2001 44 : 2425 2434.
167. Banda NK, et al. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol 2006 177 : 1904 1912.
168. Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol 2007 179 : 4101 4109.
169. Banda NK, et al. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum 2008 58 : 3081 3089.
170. Hietala MA, Nandakumar KS, Persson L, Fahlen S, Holmdahl R, Pekna M. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis. Eur J Immunol 2004 34 : 1208 1216.
171. Kagari T, Tanaka D, Doi H, Shimozato T. Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis. J Immunol 2003 170 : 4318 4324.
172. Amirahmadi SF, et al. An arthritogenic monoclonal antibody to type II collagen, CII-C1, impairs cartilage formation by cultured chondrocytes. Immunol Cell Biol 2004 82 : 427 434.
173. Gray RE, Seng N, Mackay IR, Rowley MJ. Measurement of antibodies to collagen II by inhibition of collagen fibril formation in vitro. J Immunol Methods 2004 285 : 55 61.
174. Amirahmadi SF, et al. Arthritogenic anti-type II collagen antibodies are pathogenic for cartilage-derived chondrocytes independent of inflammatory cells. Arthritis Rheum 2005 52 : 1897 1906.
175. Crombie DE, et al. Destructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro. Arthritis Res Ther 2005 7 : R927 R937.
176. Nandakumar KS, Holmdahl R. Collagen antibody induced arthritis. Methods Mol Med 2007 136 : 215 223.
177. Malmström V, Michaëlsson E, Burkhardt H, Mattsson R, Vuorio E, Holmdahl R. Systemic versus cartilage-specific expression of a type II collagen-specific T-cell epitope determines the level of tolerance and susceptibility to arthritis. Proc Natl Acad Sci USA 1996 93 : 4480 4485.
178. Michaëlsson E, Malmström V, Reis S, Burkhardt H, Engström Å, Holmdahl R. T cell recognition of carbohydrates on type II collagen. J Exp Med 1994 30 : 745 749.
179. Olofsson P, Holmberg J, Tordsson J, Lu S, Åkerström B, Holmdahl R. Positional identification of Ncf1 as a gene that regulates arthritis severity in rats. Nat Genet 2003 33 : 25 32.
180. Hagenow K, et al. Ncf1-associated reduced oxidative burst promotes IL-33R+ T cell mediated adjuvant-free arthritis in mice. J Immunol 2009 183 : 874 881.
181. Hultqvist M, Backlund J, Bauer K, Gelderman KA, Holmdahl R. Lack of reactive oxygen species breaks T cell tolerance to collagen type II and allows development of arthritis in mice. J Immunol 2007 179 : 1431 1437.
182. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004 50 : 3085 3092.
183. Gelderman KA, Hultqvist M, Holmberg J, Olofsson P, Holmdahl R. T cell surface redox levels determine T cell reactivity and arthritis susceptibility. Proc Natl Acad Sci USA 2006 103 : 12831 12836.
184. Vassilopoulos D, Calabrese LH. Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations. Arthritis Res Ther 2008 10 : 215.
185. Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G. Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation 2004 28 : 311 318.
186. Travis J, Pike R, Imamura T, Potempa J. Porphyromonas gingivalis proteinases as virulence factors in the development of periodontitis. J Periodontal Res 1997 32 : 120 125.
187. Mikuls TR, et al. Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int Immunopharmacol 2009 9 : 38 42.
188. Shi J, Sun X, Zhao Y, Zhao J, Li Z. Prevalence and significance of antibodies to citrullinated human papilloma virus-47 E2345-362 in rheumatoid arthritis. J Autoimmun 2008 31 : 131 135.
189. McCluskey J, et al. Determinant spreading: lessons from animal models and human disease. Immunol Rev 1998 164 : 209 229.
190. Holmberg J, Tuncel J, Yamada H, Lu S, Olofsson P, Holmdahl R. Pristane, a non-antigenic adjuvant, induces MHC class II-restricted, arthritogenic T cells in the rat. J Immunol 2006 176 : 1172 1179.
191. Hoffmann MH, et al. The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis. J Immunol 2007 179 : 7568 7576.
192. Wernhoff P, Olofsson P, Holmdahl R. The genetic control of rheumatoid factor production in a rat model for rheumatoid arthritis. Arthritis Rheum 2003 48 : 3584 3596.
193. Rintisch C, Ameri J, Olofsson P, Luthman H, Holmdahl R. Positional cloning of the Igl genes controlling rheumatoid factor production and allergic bronchitis in rats. Proc Natl Acad Sci USA 2008 105 : 14005 14010.
194. Sakaguchi N, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003 426 : 454 460.
195. Andersson EC, et al. Definition of MHC and T cell receptor contacts in the HLA-DR4 restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc Natl Acad Sci USA 1998 95 : 7574 7579.
196. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006 54 : 613 620.
197. Anolik JH, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004 50 : 3580 3590.
198. Szodoray P, et al. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol 2004 60 : 209 218.
199. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008 67 : 917 925.
200. Kavanaugh A, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008 67 : 402 408.
201. Cambridge G, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003 48 : 2146 2154.
202. Manz RA, Radbruch A. Plasma cells for a lifetime? Eur J Immunol 2002 32 : 923 927.
203. Alarcon-Segovia D, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003 48 : 442 454.
204. Alessandri C, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004 63 : 1218 1221.
205. Atzeni F, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006 8 : R3.
206. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004 6 : R264 R272.
207. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003 48 : 2155 2162.
208. Knuckley B, Luo Y, Thompson PR. Profiling protein arginine deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem 2008 16 : 739 745.
209. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006 103 : 9685 9690.
210. Luo Y, Knuckley B, Lee YH, Stallcup MR, Thompson PR. A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc 2006 128 : 1092 1093. (Pubitemid 43190618)
211. Hagiwara T, Nakashima K, Hirano H, Senshu T, Yamada M. Deimination of arginine residues in nucleophosmin/B23 and histones in HL-60 granulocytes. Biochem Biophys Res Commun 2002 290 : 979 983.
212. Dzhambazov B, Nandakumar KS, Kihlberg J, Fugger L, Holmdahl R, Vestberg M. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J Immunol 2006 176 : 1525 1533.
213. Myers LK, Sakurai Y, Rosloniec EF, Stuart JM, Kang AH. An analog peptide that suppresses collagen-induced arthritis. Am J Med Sci 2004 327 : 212 216.
214. Piaggio E, et al. Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance. Proc Natl Acad Sci USA 2007 104 : 9393 9398.
215. Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986 324 : 258 260.
216. Corthay A, et al. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol 1998 28 : 2580 2590.
217. Brahms H, Raymackers J, Union A, de Keyser F, Meheus L, Luhrmann R. The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies. J Biol Chem 2000 275 : 17122 17129.
218. Pritzker LB, Joshi S, Harauz G, Moscarello MA. Deimination of myelin basic protein. 2. Effect of methylation of MBP on its deimination by peptidylarginine deiminase. Biochemistry 2000 39 : 5382 5388.
219. van Stipdonk MJ, et al. T cells discriminate between differentially phosphorylated forms of alphaB-crystallin, a major central nervous system myelin antigen. Int Immunol 1998 10 : 943 950.
220. Neugebauer KM, Merrill JT, Wener MH, Lahita RG, Roth MB. SR proteins are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes. Arthritis Rheum 2000 43 : 1768 1778.
221. Kraus LM, Kraus AP Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001 78 : S102 S107.
222. Stark GR. On the reversible reaction of cyanate with sulfhydryl groups and the determination of Nh2-terminal cysteine and cystine in proteins. J Biol Chem 1964 239 : 1411 1414.
223. Arlandson M, et al. Eosinophil peroxidase oxidation of thiocyanate. Characterization of major reaction products and a potential sulfhydryl-targeted cytotoxicity system. J Biol Chem 2001 276 : 215 224.
224. Mamula MJ, et al. Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins. J Biol Chem 1999 274 : 22321 22327.
225. Young AL, Carter WG, Doyle HA, Mamula MJ, Aswad DW. Structural integrity of histone H2B in vivo requires the activity of protein L-isoaspartate O-methyltransferase, a putative protein repair enzyme. J Biol Chem 2001 276 : 37161 37165.
226. Cao L, Sun D, Whitaker JN. Citrullinated myelin basic protein induces experimental autoimmune encephalomyelitis in Lewis rats through a diverse T cell repertoire. J Neuroimmunol 1998 88 : 21 29.
227. Tarcsa E, Marekov LN, Mei G, Melino G, Lee SC, Steinert PM. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem 1996 271 : 30709 30716.
228. D'Souza CA, Moscarello MA. Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1 (MMP-3) and release of an immunodominant epitope. Neurochem Res 2006 31 : 1045 1054.
229. Beniac DR, Wood DD, Palaniyar N, Ottensmeyer FP, Moscarello MA, Harauz G. Cryoelectron microscopy of protein-lipid complexes of human myelin basic protein charge isomers differing in degree of citrullination. J Struct Biol 2000 129 : 80 95.
230. Nakayama-Hamada M, Suzuki A, Furukawa H, Yamada R, Yamamoto K. Citrullinated fibrinogen inhibits thrombin-catalysed fibrin polymerization. J Biochem 2008 144 : 393 398.